PULMICORT RESPULES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PULMICORT RESPULES (PULMICORT RESPULES).
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
| Metabolism | Hepatic via CYP3A4; primarily metabolized to 16α-hydroxyprednisolone and 6β-hydroxybudesonide. |
| Excretion | Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h. |
| Half-life | Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 3-4 L/kg. Indicates extensive tissue distribution and high lipophilicity. |
| Bioavailability | Inhalation via nebulizer: approximately 10-15% of delivered dose reaches systemic circulation; oral bioavailability <1% due to first-pass metabolism. |
| Onset of Action | Inhalation via nebulizer: clinical improvement within 2-8 days; maximum effect may take 2-4 weeks. |
| Duration of Action | Duration up to 12 hours after nebulization; sustained effect with regular dosing. Clinical note: not for acute bronchospasm. |
| Molecular Weight | 430.53 |
| Action Class | Inhaled Corticosteroid |
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
| Dosage form | SUSPENSION |
| Renal impairment | No dosage adjustment required for renal impairment; drug undergoes extensive hepatic metabolism with minimal renal excretion. |
| Liver impairment | No specific guidelines for Child-Pugh; caution advised in severe hepatic impairment due to potential reduced clearance, but no routine dose adjustment recommended. |
| Pediatric use | Children 12 months to 8 years: 0.25 mg to 0.5 mg twice daily, or 0.5 mg once daily; for moderate-to-severe asthma, up to 1 mg twice daily; infants under 12 months: 0.25 mg twice daily or 1 mg once daily (limited data). Use nebulizer with appropriate mask or mouthpiece. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased systemic effects; monitor for adrenal suppression and bone density loss with long-term use. |
| 1st trimester | Limited data; inhaled corticosteroids are generally considered safe. No increased risk of major malformations observed in human studies. |
| 2nd trimester | Safe for use; monitor for fetal growth restriction, but no evidence of increased risk. |
| 3rd trimester | Safe; monitor for neonatal adrenal suppression if high doses used, but risk low. |
Clinical note
Comprehensive clinical and safety monograph for PULMICORT RESPULES (PULMICORT RESPULES).
| Placental transfer | Minimal; budesonide undergoes extensive first-pass metabolism resulting in low systemic bioavailability, limiting placental transfer. |
| Breastfeeding | Minimal transfer into breast milk; amounts are very low (less than 1% of maternal dose). No adverse effects reported in infants. Benefit to mother outweighs negligible risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | Cough, Dysphonia, Throat irritation, Headache, Nausea, Viral respiratory infections |
| Serious Effects | Adrenal insufficiency, Increased risk of pneumonia in patients with COPD, Oropharyngeal candidiasis, Growth suppression in children, Osteoporosis with long-term use, Cataracts and glaucoma, Hypersensitivity reactions including anaphylaxis |
Hypersensitivity to budesonide or any ingredient
| Precautions | Risk of adrenal insufficiency with systemic absorption, Increased susceptibility to infections, Oropharyngeal candidiasis, Growth suppression in pediatric patients, Ocular effects (glaucoma, cataracts) |
| Food/Dietary | No clinically significant food interactions reported. |
Loading safety data…
| Lactation Rating |
| L1 (Safest) |
| Teratogenic Risk | Inhaled corticosteroids like budesonide are not associated with increased risk of congenital malformations in first trimester; second and third trimester use may increase risk of preterm birth and low birth weight but benefits of asthma control outweigh risks. |
| Fetal Monitoring | Monitor maternal asthma symptoms, peak expiratory flow, and fetal growth via ultrasound; assess for intrauterine growth restriction; monitor for signs of adrenal suppression in mother or infant with prolonged high-dose use. |
| Fertility Effects | No significant adverse effects on fertility in animal studies; in humans, uncontrolled asthma may impair fertility, but budesonide use is not linked to reduced fertility. |
| Clinical Pearls | Use a jet nebulizer with a face mask or mouthpiece; rinse mouth after use to prevent oral candidiasis. If also using a bronchodilator, administer it first. Do not mix with other drugs in the nebulizer. Titrate to lowest effective dose. Monitor for growth suppression in children. |
| Patient Advice | Use exactly as prescribed; do not stop suddenly. · Rinse mouth with water after each use to prevent thrush. · Clean nebulizer according to manufacturer instructions. · This is a maintenance medication, not for acute attacks. · If you miss a dose, skip it; do not double the next dose. · Report worsening symptoms or need for increased rescue inhaler. |